CBS News
How a love story launched the company behind Ozempic, Wegovy | 60 Minutes
Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe’s largest company as global demand for its drugs have soared.
But the Danish pharmaceutical company’s origins were motivated by more personal reasons, not financial.
The company was launched in the early 1920s by Nobel laureate August Krogh and his wife Marie, a doctor living with diabetes. At the time, diabetes was a death sentence. The couple met at the Danish Medical School, where August was Marie’s professor.
“He fell in love with her right away,” said Hanne Sindbaek, a Danish journalist and author of two books about Novo Nordisk and the Kroghs.
While on a trip to North America they learned that Canadian scientists were working on a miracle cure for diabetes: insulin.They traveled to Toronto and came home to Denmark with the rights to manufacture the life-saving drug in Scandinavia.
Launching the world’s largest philanthropic organization
There was a catch when the Canadians shared the insulin formula with the Kroghs.
“They asked that nobody should profit from it,” Sindbaek said. “It should be to the benefit of humanity. It was a way to get this life-saving drug out in the world fast.”
Back in Denmark, the Kroghs set up the Nordisk Insulin Company. To keep their agreement with the Canadian scientists, they established a nonprofit foundation, which today controls 77% of the voting shares. Today it is the largest philanthropic organization in the world, bigger than the Gates Foundation.
“The agreement was that if there were revenues and proceeds from the sales of insulin here in Scandinavia, it should be returned to society in the form of support for research into physiology and medicine,” said Mads Krogsgaard, the Novo Nordisk Foundation’s CEO.
In 2023, the foundation awarded more than $1 billion to projects in education, health and development projects around the world.
Novo Nordisk faces pricing complaints
In the years since its founding, Novo Nordisk has grown to be worth $600 billion, and yet current CEO Lars Fruergaard Jørgensen — only the fifth in the company’s history — has a compensation package of roughly $10 million, an amount dwarfed by his U.S. counterparts. When asked about the pressures of running the biggest company in Europe, he defers to the company mantra, the Novo Nordisk Way.
“So the Novo Nordisk way is the basic thinking of our founders. And key elements linked to how we treat each other, how we collaborate,” Jørgensen said. “And that’s about being open and honest. It’s all about being accountable.”
In the U.S. however, there is a growing chorus of complaints over the costs of Ozempic and Wegovy led by Sen. Bernie Sanders. Novo Nordisk’s CEO appeared before Sanders and his Senate subcommittee on Sept. 24.
Sanders excoriated Jørgensen over allegations of price gouging, saying the company’s U.S. prices are unaffordable for those who need the drugs the most. Novo Nordisk’s response is that the drugs’ benefits to global health will, ultimately, save health care systems trillions of dollars. The company also blames America’s fractured health care system for the high prices.
CBS News
Boeing machinists vote to accept labor contract, ending 7-week strike
Boeing’s 33,000 unionized machinists on Wednesday voted to approve the plane manufacturer’s latest contract offer, ending a seven-week strike that had halted production of most of the company’s passenger planes.
The union said 59% voted to accept the contract. Members have the option of returning to work as soon as Wednesday, but must be back at work by Tuesday, November 12, the union said in a statement.
Union leaders had strongly urged members to ratify the latest proposal, which would boost wages by 38% over the four-year life of the contract, up from a proposed increase of 35% that members of the International Association of Machinists and Aerospace Workers (IAM) had rejected last month.
The revised deal also provides a $12,000 cash bonus to hourly workers and increased contributions to retirement savings plans. The enhanced offer doesn’t address a key sticking point in the contentious talks — restoration of pensions — but Boeing would raise its contributions to employee 401K plans.
Average annual pay for machinists, now $75,608, would climb to $119,309 in four years under the current offer, Boeing said.
The vote came after IAM members in September and October rejected lesser offers by the Seattle-based aerospace giant.
“In every negotiation and strike, there is a point where we have extracted everything we can in bargaining and by withholding our labor,” the International Association of Machinists and Aerospace Workers stated last week in backing Boeing’s revised offer. “We are at that point now and risk a regressive or lesser offer in the future.”
Acting U.S. Labor Secretary Julie Su has played an active role in the negotiations, after recently helping to end a days-long walkout that briefly closed East and Gulf Coast ports.
The Boeing strike that began on Sept. 13 marked the latest setback for the manufacturing giant, which has been the focus of multiple federal probes after a door plug blew off a 737 Max plane during an Alaska Airlines flight in January. The incident revived concerns about the safety of the aircraft after two crashed within five months in 2018 and 2019, killing 346 people.
Boeing in July agreed to plead guilty to conspiracy to commit fraud for deceiving regulators who approved the 737 Max.
During the strike, Boeing was unable to produce any new 737 aircraft, which are made at the company’s assembly plants in the Seattle area. One major Boeing jet, the 787 Dreamliner, is manufactured at a nonunion factory in South Carolina.
The company last month reported a third-quarter loss of $6.1 billion.
contributed to this report.
CBS News
11/4: CBS Evening News – CBS News
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.
CBS News
11/4: The Daily Report – CBS News
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.